Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29170280.
- Also identified by DOI 10.1126/science.aal5240 and PMC identifier 5823247.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Colorectal cancers comprise a complex mixture of malignant cells, nontransformed cells, and microorganisms. <i>Fusobacterium nucleatum</i> is among the most prevalent bacterial species in colorectal cancer tissues. Here we show that colonization of human colorectal cancers with <i>Fusobacterium</i> and its associated microbiome-including <i>Bacteroides</i>, <i>Selenomonas</i>, and <i>Prevotella</i> species-is maintained in distal metastases, demonstrating microbiome stability between paired primary and metastatic tumors. In situ hybridization analysis revealed that <i>Fusobacterium</i> is predominantly associated with cancer cells in the metastatic lesions. Mouse xenografts of human primary colorectal adenocarcinomas were found to retain viable <i>Fusobacterium</i> and its associated microbiome through successive passages. Treatment of mice bearing a colon cancer xenograft with the antibiotic metronidazole reduced <i>Fusobacterium</i> load, cancer cell proliferation, and overall tumor growth. These observations argue for further investigation of antimicrobial interventions as a potential treatment for patients with <i>Fusobacterium</i>-associated colorectal cancer.
Medical subject headings
- Adenocarcinoma
- Anti-Bacterial Agents
- Colorectal Neoplasms
- Fusobacterium
- Metronidazole
- Microbiota